Endoplasmic Reticulum-to-Mitochondria Calcium Transfer in Pancreatic Cancer Development, Metastasis, and Treatment

胰腺癌发生、转移和治疗中的内质网至线粒体钙转移

基本信息

  • 批准号:
    10443604
  • 负责人:
  • 金额:
    $ 51.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-15 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

Pancreatic adenocarcinoma (PDAC) is a particularly lethal form of cancer that kills over 40,000 Americans every year. PDAC is most often diagnosed when disease is advanced, with metastases that lead to death. Patient outcomes are further negatively-impacted by a typical poor response to currently-available treatments. It is thus critical to develop a stronger understanding of the processes which lead to PDAC development and metastasis, as well as to determine novel, more-efficacious targets for therapies. Low-level, constitutive endoplasmic reticulum (ER)-to-mitochondria transfer of calcium is required for optimal bioenergetics and cancer-cell survival. We hypothesize that this pathway contributes to pancreatic cancer development, metastasis, and tumor maintenance, and may therefore present a viable anticancer target. The ER-localized IP3R calcium-release ion channel and the mitochondrial calcium-uniporter ion channel, MCU, mediate calcium transfer between the two organelles at membrane-contact sites. However, it has been impossible to target this pathway in vivo because of the lack of selective, cell-permeable pharmacological agents against these ion channels. We therefore propose to examine the role of ER-to-mitochondria calcium transfer in PDAC development, metastasis, and tumor maintenance through the use of novel animal and cell-culture models. We will genetically delete MCU during early development in a murine genetic-model of PDAC, the KPCY mouse, to observe the role of this protein in tumor development. In addition, we will use tumor cells as well as genetically- modified cells using Cre/lox and CRISPR/Cas9 systems, as well as patient-derived cell lines and the established human PDAC cell line, Panc-1. We will assay proliferation, cellular bioenergetics, oxygen consumption rates, and mitochondrial calcium homeostasis, using biochemical, cell biological and biophysical approaches, including electrophysiology, live-cell imaging and fluorimetry, to define the role of ER-to- mitochondria calcium transfer in these processes. To determine the role of MCU in metastasis, we will quantify metastasis in the KPCY model using the sensitive YFP-reporter gene, and we will use an in vivo tail-vein metastasis model with genetically-modified Panc-1 cells expressing luciferase in NOD/SCID mice, as well as in vitro transwell-invasion and gel-degradation assays, and biochemical and morphological assessment of metastasis-associated markers of epithelial-to-mesenchymal transition. To observe the role of ER-to- mitochondria calcium transfer in tumor maintenance and thus its therapeutic potential for more advanced disease, we will use an inducible CRISPR/Cas9 cell-culture model of murine PDAC in vitro and an in vivo inducible orthotopic model to observe the effects of acute MCU ablation in already-growing tumors and cells as a method to simulate profound pharmacological inhibition. These studies will elucidate the role of ER-to- mitochondria calcium transfer in PDAC development, metastasis, and maintenance, and they may inform future development of novel therapeutic targets in PDAC, potentially saving lives.
胰腺腺癌(PDAC)是一种特别致命的癌症,导致超过4万美国人死亡

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Kevin FOSKETT其他文献

James Kevin FOSKETT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Kevin FOSKETT', 18)}}的其他基金

Endoplasmic Reticulum-to-Mitochondria Calcium Transfer in Pancreatic Cancer Development, Metastasis, and Treatment
胰腺癌发生、转移和治疗中的内质网至线粒体钙转移
  • 批准号:
    10679078
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Molecular physiology of intracellular InsP3R and MCU ion channels
细胞内 InsP3R 和 MCU 离子通道的分子生理学
  • 批准号:
    10614508
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Endoplasmic Reticulum-to-Mitochondria Calcium Transfer in Pancreatic Cancer Development, Metastasis, and Treatment
胰腺癌发生、转移和治疗中的内质网至线粒体钙转移
  • 批准号:
    10208636
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Molecular physiology of intracellular InsP3R and MCU ion channels
细胞内 InsP3R 和 MCU 离子通道的分子生理学
  • 批准号:
    10170553
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Molecular physiology of intracellular InsP3R and MCU ion channels
细胞内 InsP3R 和 MCU 离子通道的分子生理学
  • 批准号:
    10398929
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Molecular physiology of CALHM ion channels
CALHM 离子通道的分子生理学
  • 批准号:
    10647746
  • 财政年份:
    2020
  • 资助金额:
    $ 51.61万
  • 项目类别:
Molecular physiology of CALHM ion channels
CALHM 离子通道的分子生理学
  • 批准号:
    10430169
  • 财政年份:
    2020
  • 资助金额:
    $ 51.61万
  • 项目类别:
Identification of CALHM proteins as ion channels
CALHM 蛋白作为离子通道的鉴定
  • 批准号:
    10044119
  • 财政年份:
    2020
  • 资助金额:
    $ 51.61万
  • 项目类别:
Molecular physiology of CALHM ion channels
CALHM 离子通道的分子生理学
  • 批准号:
    10192500
  • 财政年份:
    2020
  • 资助金额:
    $ 51.61万
  • 项目类别:
Role of CALHM1 ion channel in taste transduction
CALHM1离子通道在味觉传导中的作用
  • 批准号:
    8650279
  • 财政年份:
    2013
  • 资助金额:
    $ 51.61万
  • 项目类别:

相似海外基金

Setting a new research agenda in North American pediatric acute lymphoblastic leukemia
制定北美儿童急性淋巴细胞白血病的新研究议程
  • 批准号:
    486909
  • 财政年份:
    2023
  • 资助金额:
    $ 51.61万
  • 项目类别:
    Miscellaneous Programs
Risk and Resilience in Urban Black American Acute Trauma Survivors
美国城市黑人急性创伤幸存者的风险和复原力
  • 批准号:
    10379585
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study
非裔美国儿童急性淋巴细胞白血病的混合分析:ADMIRAL 研究
  • 批准号:
    10307680
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Risk and Resilience in Urban Black American Acute Trauma Survivors
美国城市黑人急性创伤幸存者的风险和复原力
  • 批准号:
    10489823
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Risk and Resilience in Urban Black American Acute Trauma Survivors
美国城市黑人急性创伤幸存者的风险和复原力
  • 批准号:
    10687026
  • 财政年份:
    2021
  • 资助金额:
    $ 51.61万
  • 项目类别:
Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study
非裔美国儿童急性淋巴细胞白血病的混合分析:ADMIRAL 研究
  • 批准号:
    10902170
  • 财政年份:
    2020
  • 资助金额:
    $ 51.61万
  • 项目类别:
Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study
非裔美国儿童急性淋巴细胞白血病的混合分析:ADMIRAL 研究
  • 批准号:
    10626271
  • 财政年份:
    2020
  • 资助金额:
    $ 51.61万
  • 项目类别:
Climate Change, Heat Exposure and Acute Morbidity in a Native American Population
气候变化、高温暴露和美洲原住民的急性发病率
  • 批准号:
    8901484
  • 财政年份:
    2014
  • 资助金额:
    $ 51.61万
  • 项目类别:
Chemokine-related acute lung injury pathogenesis in African-American patients
非裔美国患者趋化因子相关的急性肺损伤发病机制
  • 批准号:
    8425913
  • 财政年份:
    2013
  • 资助金额:
    $ 51.61万
  • 项目类别:
Chemokine-related acute lung injury pathogenesis in African-American patients
非裔美国患者趋化因子相关的急性肺损伤发病机制
  • 批准号:
    9015476
  • 财政年份:
    2013
  • 资助金额:
    $ 51.61万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了